The US has exempted specific specialty drugs and ingredients from a 100% tariff for 20 countries, including India, under Section 232 of the Trade Expansion Act. This strategic move aims to boost domestic production while protecting critical supply chains for rare disease treatments, giving Indian pharma exporters a key advantage.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Tariff Rate on Specialty Drugs: 0% (waived)
- ›Tariff on Other Patented Pharma: 100%
- ›Target this Data: 100% tariff on patented pharma, 0% on specialty drugs from 20 countries including India.
- ›Target this Nodal Body: US Commerce Department (published list in Federal Register).
- ›Target this Legal Point: Section 232 of the Trade Expansion Act.
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.